Work

Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations

Year: 2026

Type: article

Abstract: Checkpoint inhibitor-associated autoimmune diabetes (CIADM) is a life-altering and potentially life-threatening complication of immune checkpoint inhibitor (ICI) treatment in patients with cancer. Risk factors and predictors of this complication remain largely unknown. In this issue of the JCI, Wu et al. examined serum and PBMCs from 14 ICI-treated patients who developed CIADM and 28 matched controls. They identified several variables that were present prior to ICI treatment, including reduced pancreatic volume, islet autoantibodies, and biomarkers indicating immune cell activation, that together are highly predictive of development of CIADM. These findings could have profound clinical implications including treatment decisions, monitoring, and potential future prevention strategies.

Source: Journal of Clinical Investigation

DOI: 10.1172/jci202477

Authors: Kevan C. Herold, Ana Luisa Perdigoto

Institutions: Yale University, United States Department of Veterans Affairs, VA Connecticut Healthcare System

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,200